淋巴结阳性食管腺癌新辅助放化疗的治疗模式
基于2004至2015年美国国家癌症数据库,纳入8076例接受食管切除术的cT1-4aN1-3M0食管腺癌患者,其中80%接受新辅助放化疗。多因素分析显示诊断年份较晚、高容量中心及临床III期与接受新辅助放化疗相关,而年龄增长、合并症及特定地区治疗与未接受相关。接受三联治疗者生存改善(校正风险比0.80,95%CI 0.74-0.87)。
要点
- 淋巴结阳性食管腺癌中80%接受新辅助放化疗,20%未接受。
- 高龄、合并症及特定地区治疗与未接受新辅助放化疗相关。
- 三联治疗与生存改善相关(校正风险比0.80,95%CI 0.74-0.87)。
核心结论
- 多种个人、人口学及治疗中心相关因素导致淋巴结阳性食管腺癌新辅助放化疗使用差异,但新辅助治疗与生存获益相关。
研究设计与样本
- 回顾性队列研究,使用2004至2015年美国国家癌症数据库,纳入8076例接受食管切除术的cT1-4aN1-3M0食管腺癌患者。
主要发现
- 8076例患者中1616例(20%)未接受新辅助放化疗,6460例(80%)接受。
- 多因素回归显示诊断年份较晚、高容量中心治疗及临床III期与接受新辅助放化疗相关。
- 年龄增长、合并症及在中大西洋、中南或太平洋州治疗与未接受新辅助放化疗相关。
- 接受三联治疗与其他或无围手术期治疗相比,校正风险比0.80(95%CI 0.74-0.87)。
临床怎么用
- 对淋巴结阳性食管腺癌患者,应评估新辅助放化疗指征,尤其关注高龄、合并症及地区差异因素。
- 高容量中心及临床III期患者更可能接受新辅助放化疗,可作为质量改进参考。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The aims of this study were to examine the factors associated with use of neoadjuvant chemoradiotherapy (NCR) for patients with locally advanced esophageal cancer and to evaluate the effect of NCR on survival. METHODS: The 2004 to 2015 National Cancer Database was used to identify patients with cT1-4aN1-3M0 (stage II-IVA) esophageal adenocarcinoma who underwent esophagectomy. Patients were stratified by receipt of NCR. A multivariable logistic regression was performed to examine factors associated with NCR, and survival between the 2 groups was compared using a multivariable Cox model. RESULTS: Of 8076 patients meeting the study criteria, 1616 (20%) did not receive NCR and 6460 (80%) did. In a multivariable regression, factors associated with receipt of NCR were a later year of diagnosis, treatment in a high-volume center, and clinical stage III disease. Factors associated with nonreceipt of NCR were increasing age, comorbidities, and treatment in a Middle Atlantic, South Central, or Pacific state. Receipt of trimodality therapy was associated with improved survival compared with other or no perioperative therapies (adjusted hazard ratio, 0.80; 95% confidence interval, 0.74-0.87). CONCLUSIONS: Numerous personal-, demographic-, and treatment center-related factors account for variability in NCR for clinically node-positive esophageal adenocarcinoma, although neoadjuvant therapy was associated with a survival benefit. Further efforts are needed to identify reasons for these differences and design interventions to provide more equitable care for patients with esophageal cancer.
引用
- Raman V, Jawitz OK, Voigt SL, et al. Patterns of Care in Neoadjuvant Chemoradiotherapy for Node-Positive Esophageal Adenocarcinoma. Ann Thorac Surg. 2020. PMID: 32622794. doi:10.1016/j.athoracsur.2020.05.069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。